Clinical trial · Observational
Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.
NCT01398306CI-TRIAL-00076787BANNcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of this study is to analyse the concentration dopamine and serotonin in thrombocytes of patients with renal cell carcinoma and neuro-endocrine tumours compared to the concentrations of these catecholamines in healthy volunteers. The concentration dopamine and serotonin in thrombocytes with and without medication will also be evaluated.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoid Tumor | Neuroendocrine Tumor | ALIAS | 0.90 |
| Carcinoma | Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Carcinoma, Renal Cell | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
| Pancreatic Islet Cell Tumors | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sampling by vena punction. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group A
- description
- Patients with clear cell renal cell carcinoma with metastases.
- interventionNames
- Other: Blood sampling by vena punction.
- label
- Group B
- description
- Patients with low grade neuro-endocrine tumours with metastases.
- interventionNames
- Other: Blood sampling by vena punction.
Primary outcomes (1)
- measure
- Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and healthy controls, and patients with low grade neuroendocrine tumours and healthy controls.
- timeFrame
- one year
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years old or older. * Patients with clear cell renal cell carcinoma with metastases or patients with a low-grade neuro-endocrine tumor with metastases. * Written informed consent Exclusion Criteria: * Use of L-dopa or SSRI. * Patients with a second primary malignancy.
References
Publications (0)
Data not yet available
No reference posted for this study.